Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Nefiracetam and Unifiram — mechanism, side effects, legal status, and pricing.
Nefiracetam is a non-peptide small molecule in the racetam (pyrrolidinone/2-oxopyrrolidine acetamide) class, investigated as a cognitive enhancer. It was never approved by the FDA, EMA, or Japan's PMDA; Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002 after a repeat Phase III trial in dementia failed to demonstrate efficacy. A US/Canada Phase II trial in poststroke depression (600 mg and 900 mg/day) showed no overall separation from placebo, though a subgroup analysis suggested benefit in the most severely depressed patients at 900 mg. No validated therapeutic dose or approved indication exists; it is sold by research-chemical and laboratory-reagent suppliers for research use only.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
Nefiracetam
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Nefiracetam
No pricing data yet.
Check Nefiracetam prices →Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
Nefiracetam
2
COAs
99.6%
Avg purity
2
Labs
Unifiram
1
COAs
99.4%
Avg purity
1
Labs
Human clinical data are limited and largely negative or mixed. Japanese Phase II/III trials in dementia/cognitive sequelae after cerebrovascular disorders showed improvement over placebo in some early trials, but a Ministry of Health-mandated repeat Phase III trial under revised guidelines failed to demonstrate efficacy, and Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002. A US/Canada multicenter randomized double-blind Phase II trial (28 sites, 1999–2001, n=159) tested nefiracetam 600 mg and 900 mg/day vs. placebo for poststroke depression; the drug did not separate from placebo overall (response >70%, remission >40% in both arms) but showed significant benefit in the most-severely-depressed subgroup at 900 mg (Robinson et al., J Neuropsychiatry Clin Neurosci 2008). A related post hoc analysis examined apathy outcomes in the same cohort. Preclinical findings include: rat cortical neurons showed potentiation of native α4β2-type nicotinic acetylcholine receptor currents via a G(s)-protein-dependent pathway; rat dorsal root ganglion neurons showed dual concentration-dependent effects on GABA_A receptor-channel currents mediated via cAMP-dependent protein kinase and Gi/Go proteins; rat neuronal preparations showed enhancement of high-voltage-activated N/L-type Ca²⁺ channel currents and modulation of NMDA receptor function via PKC-dependent phosphorylation; rat passive avoidance models showed reversal of apomorphine-induced amnesia and preservation of hippocampal NCAM-mediated memory consolidation during scopolamine disruption.
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
Nefiracetam and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs